(ALIM) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 24, 2013
(Phil’s Stock World,
11/11/11)
Courtesy of Benzinga. Alimera Sciences (NASDAQ: ALIM) received a CRL from the FDA today, as the agency rejected Iluvien, a drug [...]
FDA Issues Complete Response Letter to Alimera Sciences Regarding New Drug Application for ILUVIE...
(Penny Stock DD,
12/24/10)
ATLANTA, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that...(read more)
(Benzinga,
10/14/10)
Alimera Sciences, Inc. (Nasdaq: ALIM) announced today that it has obtained a $32.5 million senior secured credit facility to help fund its working capital requirements. The credit facility consists of a $20 million revolving line of...(read more)
Alimera Sciences (ALIM) Company Overview
There is no analysis for ALIM yet. But you can go to Wikinvest to help create one!
